Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
GlobalData on MSN2d
FDA approves PureTech’s KarXT to treat schizophrenia in adultsPureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
KarXT is a twice-daily oral medication for adults that combines ... Bristol Myers Squibb will sell the drug combination under the brand name Cobenfy. The pharmaceutical company hasn't said how much it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback